We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Novo Nordisk Study

Efficacy and Safety Investigation of NNC0194-0499 Co-administered with Semaglutide in Subjects with Non-Alcoholic Steatohepatitis: A Dose-Ranging, Placebo-Controlled Trial

liver illustration
AGE: 18+ years old
TYPE: Interventional Drug Study
CONDITION: Nonalcoholic Steatohepatitis (NASH)
LOCATION: UH Cleveland Medical Center

Learn More

For more information, please contact the study coordinator, Katie Northcutt at 216-286-0220 or complete the online form below.

Study Purpose

The purpose of this research study is to see if a combination of 2 medicines (NNC0194-0499 and semaglutide) can reduce liver damage in patients with NASH.

Who Can Participate

Participants 18 years and older with a diagnosis of NASH may be eligible for this study.

Request More Information

To learn more about this study, please fill out the form below to request more information.

I'm not a robot